U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/mtm/cephradine.html | http://www.medicinenet.com/cephradine-oral/article.htm | https://www.ncbi.nlm.nih.gov/pubmed/4684646

Cephradine is a semisynthetic cephalosporin antibiotic. Cephradine is active against the following organisms in vitro: Group A beta-hemolytic streptococci; Staphylococci, including coagulase-positive, coagulase-negative, and penicillinase-producing strains; Streptococcus pneumoniae (formerly Diplococcus pneumoniae); Escherichia coli; Proteus mirabilis; Klebsiella species; Hemophilus influenza. It works by stopping the growth of bacteria. It is used to treat a wide variety of bacterial infections (e.g., skin, ear, respiratory and urinary tract infections). Pseudomembranous colitis has been reported in patients receiving cephradine both orally and intravenously. Diarrhea generally starts 1 to 16 days after starting cephradine therapy. Gastrointestinal side effects have included nausea, vomiting. Hypersensitivity reactions have included rash, urticaria, pruritus, and joint pain. Bacteriostats may interfere with the bactericidal action of cephalosporins in acute infection; other agents, e.g., aminoglycosides, colistin, polymyxins, vancomycin, may increase the possibility of nephrotoxicity.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
VELOSEF '125'

Approved Use

Cephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis).

Launch Date

1974
Curative
VELOSEF '125'

Approved Use

Cephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis).

Launch Date

1974
Curative
VELOSEF '125'

Approved Use

Cephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis).

Launch Date

1974
Curative
VELOSEF '125'

Approved Use

Cephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis).

Launch Date

1974
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
17.7 μg/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEPHRADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
27.5 μg × h/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEPHRADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.61 h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEPHRADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Cutaneous vasculitis due to ciprofloxacin.
1992 Jul 4
Factors associated with antibiotic resistance in coliform organisms from community urinary tract infection in Wales.
2001 Mar
[Antibiotic resistance of staphylococci isolated from outpatients].
2002
Effect of UV-B radiation on some common antibiotics.
2002 Apr
Initial study of using a laminar fluid diffusion interface for sample preparation in high-performance liquid chromatography.
2002 Apr 19
Clinical significance and epidemiology of NO-1, an unusual bacterium associated with dog and cat bites.
2002 Feb
Regression of mucosa-associated lymphoid tissue lymphoma of the bladder after antibiotic therapy.
2002 Feb 1
Transport and utilization of arginine and arginine-containing peptides by rat alveolar macrophages.
2002 Jun
Comparison of local povidone-iodine antisepsis with parenteral antibacterial prophylaxis for prevention of infective complications of TURP: a prospective randomized controlled study.
2002 Mar
Evaluation of UV-radiation induced singlet oxygen generation potential of selected drugs.
2002 May
Antimicrobial resistance pattern of Escherichia coli causing urinary tract infections, and that of human fecal flora, in the southeast of Iran.
2002 Summer
Synthesis and antibacterial activity of cephradine metal complexes: part I complexes with magnesium, calcium, chromium and manganese.
2003 Jan
Uptake of dipeptide and beta-lactam antibiotics by the basolateral membrane vesicles prepared from rat kidney.
2003 Jan 10
Sensitive determination of a beta-lactam antibiotic, cefaclor by liquid chromatography with chemiluminescence detection.
2003 Jan 15
Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: An eradication protocol.
2003 Sep
Microbiology and drug sensitivity patterns of chronic suppurative otitis media.
2004 Aug
Molecularly imprinted solid phase extraction-pulsed elution-mass spectrometry for determination of cephalexin and alpha-aminocephalosporin antibiotics in human serum.
2004 Nov 15
Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics.
2004 Sep
Nateglinide uptake by a ceftibuten transporter in the rat kidney brush-border membrane.
2005 Aug 30
Synthesis and antibacterial activity of cephradine metal complexes : part II complexes with cobalt, copper, zinc and cadmium.
2005 Jan
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
2005 Jan
H+-dependent transport mechanism of nateglinide in the brush-border membrane of the rat intestine.
2005 Jan
Purification and characterization of inducible cephalexin synthesizing enzyme in Gluconobacter oxydans.
2005 Mar
Determination of ceftriaxone in cerebrospinal fluid by ion-pair liquid chromatography.
2005 Mar-Apr
Systemic and local antibiotic prophylaxis in the prevention of Staphylococcus epidermidis graft infection.
2005 Oct 21
Preparation and characterization of uniform nanosized cephradine by combination of reactive precipitation and liquid anti-solvent precipitation under high gravity environment.
2005 Sep 14
[Bacterial pathogens and resistance patterns in community acquired pediatric urinary tract infection: experience of 152 cases].
2006 Apr
Increasing single and multi-antibiotic resistance in Shigella species isolated from shigellosis patients in Sana'a, Yemen.
2006 Aug
Crystal form of cephradine.
2006 Feb
A specific and rapid HPLC assay for the determination of cefroxadine in human plasma and its application to pharmacokinetic study in Korean.
2006 Feb 13
Chemiluminescence flow-injection analysis of beta-lactam antibiotics using the luminol-permanganate reaction.
2006 Jul-Aug
Cephradine antacids interaction studies.
2007 Jul
Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters.
2007 Jul 15
Determination of beta-lactam antibiotics in milk using micro-flow chemiluminescence system with on-line solid phase extraction.
2007 Jun 5
Characteristics of Streptococcus pyogenes strains isolated from Chinese children with scarlet fever.
2008 Dec
Plasmid-mediated quinolone resistance in Salmonella enterica, United Kingdom.
2008 Feb
[Prophylactic use of antibiotics in selective colorectal operation: a randomized controlled trial].
2008 Jan 15
Pharmacokinetic study of cephradine in Pakistani healthy male volunteers.
2008 Oct
Rapid and simple method for determination of cephradine in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS): application to the bioequivalence study.
2009 Dec 1
Antibiotics for mastitis in breastfeeding women.
2009 Jan 21
[Microcalorimetric investigation of two cephalosporins on colon bacteria activity].
2009 Oct
Traumatic optic neuropathy accompanying orbital grease gun injury.
2010 Apr
Patents

Sample Use Guides

For respiratory tract infections (other than lobar pneumonia) and skin and skin structure infections, the usual dose is 250 mg every 6 hours or 500 mg every 12 hours. For lobar pneumonia, the usual dose is 500 mg every 6 hours or 1 g every 12 hours. For uncomplicated urinary tract infections, the usual dose is 500 mg every 12 hours. In more serious urinary tract infections, including prostatitis, 500 mg every 6 hours or 1 g every 12 hours may be administered. Larger doses (up to 1 g every 6 hours) may be given for severe or chronic infections.
Route of Administration: Oral
In Vitro Use Guide
Sources: DOI: 10.5897/IJPS11.057
MIC 90 of Cephradine standard powder against 25 clinical isolates of S. aureus was 2048 ug/ml.
Substance Class Mixture
Created
by admin
on Mon Mar 31 18:19:16 GMT 2025
Edited
by admin
on Mon Mar 31 18:19:16 GMT 2025
Record UNII
F1BC02I72W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEPHRADINE
ORANGE BOOK   USAN   USP   VANDF  
USAN  
Official Name English
CEPHRADINE HYDRATE
MART.  
Preferred Name English
VELOSEF
Brand Name English
CEPHRADINE HYDRATE [MART.]
Common Name English
CEPHRADINE [USP-RS]
Common Name English
CEFRADINE HYDRATE
Common Name English
CEPHRADINE [VANDF]
Common Name English
SK&F-D-39304
Code English
SQ-11436
Code English
SQ-22022
Code English
CEPHRADINE [USP MONOGRAPH]
Common Name English
ANSPOR
Brand Name English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(2-AMINO-2-(1,4-CYCLOHEXADIEN-1-YL)ACETAMIDO)-3-METHYL-8-OXO-, HYDRATE, D-
Common Name English
CEPHRADINE NON-STOICHIOMETRIC HYDRATE FORM
Common Name English
SQ 11436
Code English
CEPHRADINE, UNSPECIFIED HYDRATE
Common Name English
CEPHRADINE [ORANGE BOOK]
Common Name English
CEPHRADINE [USAN]
Common Name English
SK&F D-39304
Code English
Classification Tree Code System Code
WHO-ATC J01DB09
Created by admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
NCI_THESAURUS C357
Created by admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
LIVERTOX 178
Created by admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
NDF-RT N0000175488
Created by admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C47441
Created by admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
PRIMARY
EVMPD
SUB21808
Created by admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
PRIMARY
SMS_ID
100000088255
Created by admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
PRIMARY
MESH
D002515
Created by admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
PRIMARY
ChEMBL
CHEMBL1604
Created by admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
PRIMARY
FDA UNII
F1BC02I72W
Created by admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
PRIMARY
EVMPD
SUB07417MIG
Created by admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
PRIMARY
CHEBI
3547
Created by admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
PRIMARY
IUPHAR
4830
Created by admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
PRIMARY
RXCUI
2239
Created by admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
PRIMARY RxNorm
LACTMED
Cephradine
Created by admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
PRIMARY
RS_ITEM_NUM
1102805
Created by admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Definition References